Q2 2025 · 13F-HR
Omega Fund Management, LLCholdings as filed
Filed 2025-08-14 · accession 0000950123-25-008066
$154.4M
Reported value
13
Positions
2025-06-30
Period end
The Brief · Omega Fund Management, LLC · Q2 2025
AI · grounded in 13F
Omega Fund Management, LLC established a new position in Beta Bionics Inc. BBNX valued at $28.9M. The fund also initiated new stakes in Kestra Med Technologies Ltd. KMTS for $27.3M and Upstream Bio Inc. UPB for $22.4M. Additional new positions include Nuvation Bio NUVB at $21.5M and Bicara Therapeutics Inc. BCAX at $20.5M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 08659B102 | BBNX | Beta Bionics Inc. | $28.9M | 18.7% | 1,988,287 | Common | SOLE |
| G52441105 | KMTS | Kestra Med Technologies Ltd. | $27.3M | 17.7% | 1,645,893 | Common | SOLE |
| 91678A107 | UPB | Upstream Bio Inc. | $22.4M | 14.5% | 2,036,293 | Common | SOLE |
| 67080N101 | NUVB | Nuvation Bio | $21.5M | 13.9% | 11,042,728 | Common | SOLE |
| 055477103 | BCAX | Bicara Therapeutics Inc. | $20.5M | 13.3% | 2,204,650 | Common | SOLE |
| 76029N106 | REPL | Replimune Group | $18.3M | 11.9% | 1,975,203 | Common | SOLE |
| 52886X107 | LXEO | Lexeo Therapeutics | $4.8M | 3.08% | 1,184,636 | Common | SOLE |
| 45175G108 | — | Ikena Oncology | $3.0M | 1.95% | 2,249,123 | Common | SOLE |
| 799566104 | SANA | Sana Biotechnology, Inc. | $2.3M | 1.49% | 843,750 | Common | SOLE |
| 022307102 | ALMS | Alumis Inc. | $2.0M | 1.27% | 653,223 | Common | SOLE |
| 29286M105 | — | enGene Holdings Inc. | $1.9M | 1.24% | 526,357 | Common | SOLE |
| 4525EP101 | VTLUSD | Immunic Inc. | $1.2M | 0.81% | 1,788,160 | Common | SOLE |
| 29286M113 | — | enGene Holdings Inc. | $272,955 | 0.18% | 321,502 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.